NuVasive Inc (NASDAQ: NUVA), a company involved in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced yesterday that it has named Matthew K Harbaugh as its new executive vice president and chief financial officer, effective immediately.

Harbaugh succeeds Rajesh J Asarpota, who will transition from the company.

Harbaugh has more than 25 years of experience in finance, business and strategy, and operations management. Most recently, he served as president of the specialty generics business at Mallinckrodt plc. Prior to that, he was Mallinckrodt's CFO for more than five years. He earlier held various financial management positions at Covidien Pharmaceuticals, which was spun-off from Covidien plc as Mallinckrodt plc in July 2013. He joined Covidien in 2007 and served in several finance and leadership roles, including as CFO and interim president of Covidien Pharmaceuticals. His prior experience includes around 10 years at Monsanto Company, where he held various roles in investor relations and finance and two ex-patriate positions.